402 related articles for article (PubMed ID: 25148458)
1. Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics.
Liu M; Goss PE; Ingle JN; Kubo M; Furukawa Y; Batzler A; Jenkins GD; Carlson EE; Nakamura Y; Schaid DJ; Chapman JA; Shepherd LE; Ellis MJ; Khosla S; Wang L; Weinshilboum RM
Mol Endocrinol; 2014 Oct; 28(10):1740-51. PubMed ID: 25148458
[TBL] [Abstract][Full Text] [Related]
2. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
Goss PE; Hershman DL; Cheung AM; Ingle JN; Khosla S; Stearns V; Chalchal H; Rowland K; Muss HB; Linden HM; Scher J; Pritchard KI; Elliott CR; Badovinac-Crnjevic T; St Louis J; Chapman JA; Shepherd LE
Lancet Oncol; 2014 Apr; 15(4):474-82. PubMed ID: 24636210
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
Ingle JN; Schaid DJ; Goss PE; Liu M; Mushiroda T; Chapman JA; Kubo M; Jenkins GD; Batzler A; Shepherd L; Pater J; Wang L; Ellis MJ; Stearns V; Rohrer DC; Goetz MP; Pritchard KI; Flockhart DA; Nakamura Y; Weinshilboum RM
J Clin Oncol; 2010 Nov; 28(31):4674-82. PubMed ID: 20876420
[TBL] [Abstract][Full Text] [Related]
4. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
Oesterreich S; Henry NL; Kidwell KM; Van Poznak CH; Skaar TC; Dantzer J; Li L; Hangartner TN; Peacock M; Nguyen AT; Rae JM; Desta Z; Philips S; Storniolo AM; Stearns V; Hayes DF; Flockhart DA
Breast Cancer Res Treat; 2015 Nov; 154(2):263-73. PubMed ID: 26536870
[TBL] [Abstract][Full Text] [Related]
5. Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.
Sergi G; Pintore G; Falci C; Veronese N; Berton L; Perissinotto E; Basso U; Brunello A; Monfardini S; Manzato E; Coin A
J Bone Miner Metab; 2012 Jul; 30(4):461-7. PubMed ID: 22160398
[TBL] [Abstract][Full Text] [Related]
6. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
Goss PE; Ingle JN; Pritchard KI; Ellis MJ; Sledge GW; Budd GT; Rabaglio M; Ansari RH; Johnson DB; Tozer R; D'Souza DP; Chalchal H; Spadafora S; Stearns V; Perez EA; Liedke PE; Lang I; Elliott C; Gelmon KA; Chapman JA; Shepherd LE
J Clin Oncol; 2013 Apr; 31(11):1398-404. PubMed ID: 23358971
[TBL] [Abstract][Full Text] [Related]
7. Appraising adjuvant aromatase inhibitor therapy.
Perez EA
Oncologist; 2006; 11(10):1058-69. PubMed ID: 17110624
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.
Napoli N; Rastelli A; Ma C; Yarramaneni J; Vattikutti S; Moskowitz G; Giri T; Mueller C; Kulkarny V; Qualls C; Ellis M; Armamento-Villareal R
Bone; 2013 Aug; 55(2):309-14. PubMed ID: 23643682
[TBL] [Abstract][Full Text] [Related]
9. Osteoporotic fracture risk in women with breast cancer treated with aromatase inhibitors: a health insurance claims database study in Japan.
Taguchi T; Matsushima H; Kodama S; Okubo N; Ito T; Ludwikowska M; Fukumoto S; Matsumoto T
Expert Opin Pharmacother; 2024 Feb; 25(3):325-334. PubMed ID: 38588537
[TBL] [Abstract][Full Text] [Related]
10. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
Conte P; Frassoldati A
Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
[TBL] [Abstract][Full Text] [Related]
11. Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Tang SC
Oncology; 2010; 79(1-2):13-26. PubMed ID: 21051913
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associations.
Ingle JN
Breast Cancer Res; 2010 Dec; 12 Suppl 4(Suppl 4):S17. PubMed ID: 21172079
[No Abstract] [Full Text] [Related]
13. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Yonehara Y; Iwamoto I; Kosha S; Rai Y; Sagara Y; Douchi T
J Obstet Gynaecol Res; 2007 Oct; 33(5):696-9. PubMed ID: 17845332
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression.
Liu M; Wang L; Bongartz T; Hawse JR; Markovic SN; Schaid DJ; Mushiroda T; Kubo M; Nakamura Y; Kamatani N; Goss PE; Ingle JN; Weinshilboum RM
Breast Cancer Res; 2012 Mar; 14(2):R41. PubMed ID: 22405131
[TBL] [Abstract][Full Text] [Related]
15. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
Rizzoli R; Body JJ; DeCensi A; Reginster JY; Piscitelli P; Brandi ML;
Osteoporos Int; 2012 Nov; 23(11):2567-76. PubMed ID: 22270857
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
Majithia N; Atherton PJ; Lafky JM; Wagner-Johnston N; Olson J; Dakhil SR; Perez EA; Loprinzi CL; Hines SL
Support Care Cancer; 2016 Mar; 24(3):1219-26. PubMed ID: 26298334
[TBL] [Abstract][Full Text] [Related]
17. TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression.
Liu M; Ingle JN; Fridley BL; Buzdar AU; Robson ME; Kubo M; Wang L; Batzler A; Jenkins GD; Pietrzak TL; Carlson EE; Goetz MP; Northfelt DW; Perez EA; Williard CV; Schaid DJ; Nakamura Y; Weinshilboum RM
Mol Endocrinol; 2013 Apr; 27(4):657-70. PubMed ID: 23518928
[TBL] [Abstract][Full Text] [Related]
18. Impact of an osteoporosis specialized unit on bone health in breast cancer survivals treated with aromatase inhibitors.
Martínez P; Galve E; Arrazubi V; Sala MÁ; Fernández S; Pérez CE; Arango JF; Torre I
Reumatol Clin (Engl Ed); 2019; 15(4):211-217. PubMed ID: 29032291
[TBL] [Abstract][Full Text] [Related]
19. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
20. Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Moy I; Lin Z; Rademaker AW; Reierstad S; Khan SA; Bulun SE
PLoS One; 2013; 8(11):e77543. PubMed ID: 24223121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
